Background: Sample size calculation is a key aspect in the planning of any trial. Planning a randomized placebo-controlled trial in relapsing–remitting multiple sclerosis (RRMS) requires knowledge of the annualized relapse rate (ARR) in the placebo group.
Objectives: This paper aims (i) to characterize the uncertainty in ARR by conducting a systematic review of placebo-controlled, randomized trials in RRMS and by modelling the ARR over time; and (ii) to assess the feasibility and utility of blinded sample size re-estimation (BSSR) procedures in RRMS.
Methods: A systematic literature review was carried out by searching PubMed, Ovid Medline and the Cochrane Register of Controlled Trials. The placebo ARRs were modelled by negative binomial regression. Computer simulations were conducted to assess the utility of BSSR in RRMS.
Results: Data from 26 placebo-controlled randomized trials were included in this analysis. The placebo ARR decreased by 6.2% per year (p < 0.0001; 95% CI (4.2%; 8.1%)) resulting in substantial uncertainty in the planning of future trials. BSSR was shown to be feasible and to maintain power at a prespecified level also if the ARR was misspecified in the planning phase.
Conclusions: Our investigations confirmed previously reported trends in ARR. In this context adaptive strategies such as BSSR designs are recommended for consideration in the planning of future trials in RRMS.
InusahSSormaniMPCofieldSSAbanIBMusaniSKSrinivasasainagendraV. Assessing changes in relapse rates in multiple sclerosis. Mult Scler2010; 16: 1414–1421.
2.
KapposLRadueEWO’ConnorPPolmanCHohlfeldRCalabresiP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
3.
GiovannoniGComiGCookSRammohanKRieckmannPSoelberg SørensenP. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–26.
4.
Food and Drug Administration (FDA). Guidance for industry – Adaptive design clinical trials for drugs and biologics. Draft guidance, 2010. Food and Drug Administration, 2010.
5.
CookRJBergeronPJBoherJMLieY. Two-stage design of clinical trials involving recurrent events. Stat Med2009; 28: 2617–2638.
6.
FriedeTSchmidliH. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med2010; 29: 1145–1156.
7.
FriedeTSchmidliH. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods Inf Med2010; 49: 618–624.
8.
SormaniMPLaura BonzanoLRoccatagliataLCutterGRMancardiGLBruzziP. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol2009; 65: 268–275.
9.
WangYCMeyersonLTangYQQianN. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci2009; 285: 206–211.
10.
FurmanE. On the convolution of the negative binomial random variables. Stat Probab Lett2007; 77: 169–172.
11.
NgHKTTangM-L. Testing the equality of two Poisson means using the rate ratio. Stat Med2005; 24: 955–965.
12.
FriedeTKieserM. Sample size recalculation in internal pilot study designs: a review. Biom J2006; 48: 537–555.
13.
BendaNBransonMMaurerWFriedeT. Aspects of modernizing drug development using scenario planning and evaluation. Drug Inf J2010; 44: 299–315.
14.
ChatawayJNicholasRToddSParsonsNToddSMillerD. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler2011; 17: 81–88.
15.
FriedeTNicholasRStallardNToddSParsonsNValdés-MárquezE. Refinement of the Clinical Scenario Evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Inf J2010; 44: 713–718.
16.
KapposLGoldRMillerDHMacManusDGHavrdovaELimmrothV. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet2008; 372: 1463–1472.
17.
EbersGCTraboulseeALiDLangdonDRederATGoodinDS. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry2010; 81: 907–912.
18.
Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Doc. Ref. EMEA/CHMP/EWP/561/98 Rev 1. London: CHMP, 2005.
19.
ScalfariANeuhausADegenhardtARiceGPMuraroPADaumerM. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain2010; 133: 1914–1929.
20.
ICH Harmonised Tripartite Guideline E9: Statistical principles for clinical trials. Stat Med1999; 18: 1905–1942.
21.
European Medicines Agency (EMA). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. CHMP/EWP/2459/02, 2007. Available from: http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf (accessed 12 February 2011).
22.
JennisonCTurnbullBW. Group sequential methods with applications to clinical trials. Chapman & Hall/CRC, 2000.
23.
GaydosBAndersonKBerryDABurnhamNChuang-SteinCDudinakJ. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J2009; 43: 539–556.
24.
PolmanCHReingoldSCBarkhofFCalabresiPAClanetMCohenJA. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology2008; 70: 1134–1140.
